Khartis Therapeutics Raises $50 Million in Series B
Khartis Therapeutics, a San Diego-based company specializing in developing oral therapies for immune-mediated and chronic diseases, has successfully raised $50 million in a Series B funding round. The round was led by Forge Life Science Partners, with participation from Longwood Fund, Alexandria Venture Investments, Foresite Capital, Lilly Asia Ventures, and Nextech Invest.
Key Players in the Series B Round
Forge Life Science Partners spearheaded the investment, joined by a consortium of prominent firms. Longwood Fund, Alexandria Venture Investments, Foresite Capital, Lilly Asia Ventures, and Nextech Invest also contributed to the round.
Leadership at Khartis Therapeutics
Khartis Therapeutics was co-founded by Craig Murphy, who serves as the Chief Scientific Officer, and Robert Hoffman, who acts as both CEO and Head of Research. Their leadership is integral to the company's mission of advancing drug discovery for significant health challenges.
Use of Funds
The $50 million raised will be directed towards advancing Khartis Therapeutics' pipeline of oral therapies. The company aims to enhance its research capabilities and expedite the development of its drug candidates, targeting immune-mediated and chronic diseases.
Conclusion
With this substantial funding, Khartis Therapeutics is well-positioned to make significant strides in its field, potentially offering new hope to patients dealing with chronic and immune-mediated conditions.